Literature DB >> 10706072

Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: implications for adoptive immunotherapy.

R E Brouwer1, K H Zwinderman, H C Kluin-Nelemans, S A van Luxemburg-Heijs, R Willemze, J H Falkenburg.   

Abstract

OBJECTIVE: Previously, we observed an increased recognition of malignant cells by cytotoxic T lymphocytes (CTL) when the target cells were cultured in vitro for 24 hours. In this study, we analyzed the expression of costimulatory and adhesion molecules on acute myeloid leukemia (AML) cells and determined whether 24-hour culture of the cells was associated with upregulation of these molecules. We analyzed whether this incubation period improved recognition of AML cells by CTL.
MATERIALS AND METHODS: Expression of costimulatory and adhesion molecules on leukemic blasts of 34 patients comprising each AML FAB subclassification were analyzed directly and after 24 hours of culture, and the recognition of these AML cells by an HLA-A2 restricted CTL clone was determined. Blocking studies were performed with antibodies against CD54, CD58, and CD11a.
RESULTS: Immunophenotyping showed a low expression of CD80 and CD40 and a variable CD86 expression on most AML cells. CD54 expression was generally low, CD58 expression was high, and CD11a expression was variable, with a higher expression in AML M0, M1, M4, and M5. Twenty-four hours of culture resulted in a significant upregulation of CD40, CD54, and CD58. Impaired recognition of AML cells by the HLA-A2 restricted CTL clone was enhanced 100-200% by 24 hours of preincubation of the leukemic cells. Blocking studies showed the importance of multiple adhesion molecules on the AML cells.
CONCLUSION: Low expression of multiple costimulatory and adhesion molecules on AML could be upregulated by 24 hours of culture, which was associated with increased recognition of the AML blasts by CTL. Blocking multiple adhesion molecules completely abolished CTL recognition, showing the importance of the combination of these molecules for T-cell interaction with AML.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706072     DOI: 10.1016/s0301-472x(99)00143-5

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

Review 1.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

Review 2.  Graft versus tumor effects and why people relapse.

Authors:  J H Frederik Falkenburg; Inge Jedema
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.

Authors:  Elaine M Sloand; Lori Mainwaring; Monika Fuhrer; Shakti Ramkissoon; Antonio M Risitano; Keyvan Keyvanafar; Jun Lu; Atanu Basu; A John Barrett; Neal S Young
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

4.  Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.

Authors:  Marvin M van Luijn; Martine E D Chamuleau; James A Thompson; Suzanne Ostrand-Rosenberg; Theresia M Westers; Yuri Souwer; Gert J Ossenkoppele; S Marieke van Ham; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

5.  Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.

Authors:  Peter Westervelt; Jessica L Pollock; Kristie M Oldfather; Matthew J Walter; Margaret K Ma; Anthony Williams; John F DiPersio; Timothy J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-20       Impact factor: 11.205

6.  Anti-tumor immune responses in immune-reconstituted mice injected with a tumor vaccine.

Authors:  Aili He; Wanggang Zhang; Kangling Xu; Jianli Wang; Yun Yang; Xingmei Chao
Journal:  Med Oncol       Date:  2011-07-15       Impact factor: 3.738

7.  An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML.

Authors:  Dyantha I van der Lee; Georgia Koutsoumpli; Rogier M Reijmers; M Willy Honders; Rob C M de Jong; Dennis F G Remst; Tassilo L A Wachsmann; Renate S Hagedoorn; Kees L M C Franken; Michel G D Kester; Karl J Harber; Lisanne M Roelofsen; Annemiek M Schouten; Arend Mulder; Jan W Drijfhout; Hendrik Veelken; Peter A van Veelen; Mirjam H M Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal:  Cancers (Basel)       Date:  2021-10-27       Impact factor: 6.639

8.  Expression and prognosis of the B7 family in acute myeloid leukemia.

Authors:  Wei Zhang; Wenjing Zhang; Lin Gui; Xue Yan; Xuan Zhou; Yongchao Ma; Zhinan Yang; Yu Fang; Hongmei Zhang; Jinning Shi
Journal:  Ann Transl Med       Date:  2021-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.